Share This Page
Drugs in ATC Class C08EA
✉ Email this page to a colleague
Drugs in ATC Class: C08EA - Phenylalkylamine derivatives
| Tradename | Generic Name |
|---|---|
| BEPADIN | bepridil hydrochloride |
| VASCOR | bepridil hydrochloride |
| >Tradename | >Generic Name |
Market dynamics and patent landscape for ATC Class C08EA (phenylalkylamine derivatives): exclusivity, Orange Book, and generic entry risk
Executive summary: ATC Class C08EA (phenylalkylamine calcium channel blockers) is dominated commercially by verapamil (multiple immediate- and controlled-release products) and diltiazem (also multiple release profiles), with patent and exclusivity dynamics largely driven by (i) formulation and delivery-system patents (controlled-release matrices, osmotic pumps, beads, and combination products), (ii) method-of-use patents tied to cardiovascular indications and dosing regimens, and (iii) brand-specific patent estates rather than a single class-wide patent barrier. For business planning, the highest-probability generic entry pathways are typically blocked not by the earliest active-ingredient patents (largely expired) but by later-filed product-process and controlled-release IP and by device-like delivery system IP that can constrain “AB-rated” substitutes. For litigation exposure, the most recurring patterns in this class are Paragraph IV ANDA challenges against brand-controlled-release products and disputes over formulation equivalence and carve-outs for specific dosage forms.
Which phenylalkylamine drugs dominate ATC C08EA and how do their markets move?
What drugs are in ATC C08EA?
ATC C08EA corresponds to phenylalkylamine derivatives, primarily covering:
- Verapamil
- Diltiazem
(Exact ATC sub-coverage can vary by national listing, but these are the consistent commercial anchors.)
How do demand drivers shape pricing and competition?
Market movement for this class is driven by:
- Generic penetration of older strengths and immediate-release formats.
- Shift to controlled-release to support adherence and once-daily or twice-daily regimens.
- Indication expansion and guideline changes that sustain brand differentiation via labeling and product choice.
- Payor pressure that accelerates switching to lower-cost generics once product-level exclusivities clear.
Key commercial dynamic for patent strategy
In phenylalkylamines, the “patent wall” is most often:
- Product-specific (delivery system, release profile, excipient set, manufacturing process).
- Indication-specific (method-of-use, patient subsets, titration regimens).
- Combination-specific (if the brand is paired with add-on therapy).
What patents protect verapamil and diltiazem products in ATC C08EA?
Featured-snippet answer: Protection usually clusters around controlled-release formulations, manufacturing processes, and method-of-use claims; the underlying active ingredient is typically out of active patent scope.
Patent estate buckets that matter in C08EA
Across verapamil and diltiazem brand portfolios, patenting commonly falls into:
- Controlled-release dosage form patents
- Matrix compositions
- Coated pellets/beads
- Polymer blends defining dissolution/erosion kinetics
- Geometry and coating thickness affecting release rate
- Manufacturing process patents
- Granulation parameters
- Coating processes
- Compression and curing conditions
- In-process controls tied to critical quality attributes
- Method-of-use patents
- Dosing algorithms for hypertension, angina, arrhythmias
- Patient stratification (renal impairment, elderly dosing)
- Combination regimens and sequence
- Combination product patents
- Co-formulations with antihypertensives or antianginals
- Fixed-dose titration or release synchronization
How many patents cover each brand typically?
For active brands still in contested life cycles, estates often include:
- Multiple formulation patents (often more than five per dosage form lifecycle)
- One to several method-of-use patents
- Manufacturing and scale-up patents that can extend practical exclusivity and increase generic design-around cost
(Exact counts are brand- and jurisdiction-dependent; the binding economic point is that the generic entry barrier is usually the most recent product-specific claims rather than legacy API claims.)
Which formulations are protected by phenylalkylamine derivative patents? (IR vs SR vs XR)
What formulation types most frequently carry patent protection?
In C08EA, the most enforceable formulation categories are:
- Sustained-release (SR) tablets
- Extended-release (ER/XR) capsules or tablets
- Multiparticulates (beads/pellets) with controlled coatings
- Prodrug or altered-release strategies (less common, but present in some portfolios)
- High-viscosity or controlled diffusion polymer systems
How does release mechanism affect generic “design-around” risk?
Generic filers typically focus on dissolution profile similarity. Patent risk rises when:
- Claims define specific polymer composition and release kinetics
- Claims define coating structure or multiparticulate architecture
- Claims tie release to processing parameters (not only composition)
When do ATC C08EA products lose exclusivity and what timelines govern generic entry?
What “loss of exclusivity” looks like in this class
In phenylalkylamine portfolios, exclusivity timing is usually layered:
- Core API patents expire early.
- Formulation and method-of-use patents extend the effective barrier.
- Regulatory exclusivities (where applicable) can delay generic approval even after patent expiration.
- Litigation stay from Paragraph IV can defer approval.
Typical decision timeline for a generic ANDA
A generic challenge strategy in this class typically follows:
- Identify the brand’s last blocking patents for the targeted dosage form.
- File ANDA with Paragraph IV certification on those patents.
- Expect an FDA approval clock pause if litigation is triggered.
- Launch upon:
- Early patent expiry, or
- Court ruling of invalidity or non-infringement, or
- Settlement that permits launch at a defined date.
Because patent coverage is formulation-specific, the generic product must match the claim scope for its targeted strength and release profile.
What generic entry risks exist for verapamil and diltiazem controlled-release products?
What are the highest-risk scenarios for ANDA entrants?
The risk profile is elevated when:
- The brand estate includes multiple formulation patents covering the ER/SR dosage form.
- The claimed technology involves multiparticulate coating or polymer blends that are hard to match functionally.
- The brand asserts process patents that require detailed proof of infringement.
- The brand has a history of enforcing in litigation or entering settlements that preserve a later launch date.
What “safe” pathways exist?
Generic entrants reduce risk by:
- Switching to an alternative release type not covered by the asserted claims.
- Using a formulation with materially different release mechanism.
- Pursuing non-infringing design-arounds aimed at avoiding specific composition or structural claim elements.
What is the Orange Book status of ATC C08EA phenylalkylamine drugs?
How to interpret Orange Book listings for this class
For C08EA, the practical Orange Book lesson is:
- Look for blocking patents mapped to specific dosage forms (not just the drug name).
- Identify which patents are:
- Composition of matter
- Method of use
- Formulation/dosage form
- Manufacturing
- Map each patent to the ANDA entry strength and release type.
Actionable interpretation for business: A “drug-level” view overstates certainty. Launch risk is determined by patent-to-product mapping, with the latest product-specific patents typically dominating exclusivity outcomes.
What patent litigation affects phenylalkylamine derivative markets?
What litigation patterns are common in C08EA
Across verapamil and diltiazem brand portfolios, common dispute themes include:
- Alleged infringement of controlled-release formulation claims
- Dispute over equivalence of dissolution profile and release mechanism
- Process patent disputes tied to manufacturing conditions
- Settlement-driven launch windows that create predictable reentry dates
How settlements shape market dynamics
Settlements in this class often:
- Permit generic entry on a defined date (so-called “launch carve-out”)
- Allow limited launch for some strengths first, then broader coverage later
- Include stipulations that affect patent enforcement boundaries
How does ATC C08EA compare with other calcium channel blocker classes on the patent curve?
What differs from dihydropyridines (C08CA) and other groups?
Compared with dihydropyridines:
- Phenylalkylamine derivatives often have more mature, widely genericized markets for legacy formats.
- Residual brand value tends to concentrate in ER/SR differentiation and combination indications rather than broad exclusivity on the active ingredient.
- Patent estates remain meaningful but usually narrower in scope and easier to “route around” by selecting alternative formulations, strengths, or release types.
Which companies are best positioned in C08EA, and how does patent strength correlate with share?
Commercial positioning
The leading commercial position typically aligns with:
- Brands with strong controlled-release IP and established payer contracts
- Generic manufacturers with experience designing around dose-form and release-mechanism claims
- Entrants that can litigate and launch at scale once a settlement or court decision clears barriers
Business inference
Patent strength correlates less with “number of patents” and more with:
- Whether the latest patents are mapped to the highest-volume dosage forms
- Whether claims are composition/mechanism-defining versus broadly drafted
- Whether the brand enforces consistently in Paragraph IV disputes
What is the biologics/biosimilar risk in C08EA?
None. ATC C08EA phenylalkylamine derivatives are small-molecule calcium channel blockers. The biosimilar framework does not apply.
Key patent estate build strategy for new entry into phenylalkylamine derivatives (defensive and offensive)
If launching a brand-like product, what claims matter?
For a new or reformulated verapamil/diltiazem product, the most enforceable claim targets are:
- Controlled-release composition (specific polymer/excipient systems)
- Dosage form architecture (layering, multiparticulate geometry, coating parameters)
- Manufacturing process (controllable steps tied to critical quality attributes)
- Method-of-use with a credible clinical differentiation (patient population or titration sequence)
If filing an ANDA, where do you focus for non-infringement?
- Release-mechanism elements that claims define by composition or structural features
- Coating/pellet architecture elements
- Process parameters that can change the resulting dissolution behavior
Key Takeaways
- ATC C08EA is anchored by verapamil and diltiazem; market competition is shaped mainly by controlled-release formulation differentiation and brand-specific patent estates rather than active-ingredient patents.
- The most consequential exclusivity barriers are typically product- and release-type-specific patents that map to SR/ER formulations.
- Generic entry risk rises when the brand portfolio includes multiple formulation and/or manufacturing/process patents covering the highest-volume dosage forms.
- Orange Book value is maximized by patent-to-dosage form mapping; “drug-level” status can mislead.
- Litigation and settlements most often determine effective market timing through approval stays and launch carve-outs.
FAQs
- Do phenylalkylamine derivative patent estates usually expire by drug substance or by specific ER/SR dosage form?
- What is the typical strategy for Paragraph IV ANDA challengers against controlled-release verapamil/diltiazem products?
- How do formulation patents differ from method-of-use patents in practical infringement disputes for this class?
- Can a generic reduce litigation risk by switching from ER to IR or by using a different release mechanism?
- Which patent claim types most often drive settlements in calcium channel blocker controlled-release litigations?
References
No cited sources were provided in the input, and no reliable Orange Book/patent-number dataset is included here to support citation-grade accuracy.
More… ↓
